|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 11,166,947: Scope, Claims, and Patent Landscape
Executive Summary
US Patent 11,166,947, granted to Gilead Sciences, Inc. on November 30, 2021, protects specific innovations in the realm of antiviral therapeutics, notably within the context of coronavirus treatment. This patent claims new compositions, methods of use, and formulations targeting viral infections, particularly emphasizing nucleotide analogues and their derivatives. Its scope reflects an extensive effort to establish broad protection covering compounds, methods of administration, and associated therapeutic uses.
The patent's claims focus on novel chemical entities and their pharmaceutical applications, with a clear intent to secure exclusivity over a particular class of antiviral agents. The patent landscape surrounding this invention situates it amid seminal patents related to nucleoside analogues, antiviral formulations, and COVID-19 treatments, notably within Gilead’s portfolio and competing patents from other biotech firms.
This report dissects the patent’s scope and claims, explores the relevant patent landscape, and contextualizes its strategic significance in antiviral drug development.
1. Overview of US Patent 11,166,947
Title: Nucleoside Analogues for the Treatment of Viral Infections
Filing Date: May 16, 2019
Grant Date: November 30, 2021
Assignee: Gilead Sciences, Inc.
International Application: PCT/US2019/031635
Summary
The patent claims cover specific nucleoside analogue compounds, their pharmaceutical compositions, and methods for treating viral infections, especially coronaviruses (e.g., SARS-CoV-2). It builds upon prior Gilead research, notably remdesivir (originally US Patent 9,888,277), innovating by proposing new derivatives with enhanced efficacy, pharmacokinetics, and safety profiles.
2. Scope of the Claims
2.1. Main Claim Categories
| Claim Type |
Description |
| Chemical Compounds |
Novel nucleoside analogues with specified structural features, including modifications to sugar moieties and nucleobase components. |
| Pharmaceutical Compositions |
Compositions comprising the claimed compounds, potentially including carriers, stabilizers, and adjuvants. |
| Methods of Use |
Methods for treating or preventing viral infections, with embodiments targeting coronaviruses, including achieving antiviral activity in humans or animals. |
| Combination Therapies |
Use of the compounds in conjunction with other antiviral agents, immunomodulators, or supportive therapeutics. |
2.2. Key Structural Features Covered
The patent broadly claims compounds with:
- Modified ribose or deoxyribose sugar components.
- Nucleobase modifications, such as substituted purines or pyrimidines.
- Phosphorylated intermediates, prodrugs, or delivery systems enhancing bioavailability.
- Variations that improve stability, selectivity, or reduce toxicity.
This breadth aims to preempt competitors designing similar analogues while focusing on the antiviral activity spectrum.
2.3. Claim Scope Analysis
| Claim Number |
Focus |
Description |
Coverage Scope |
| Claim 1 |
Core compound |
A compound comprising a specified nucleoside analogue with particular substitutions. |
Broad, covering any compound conforming to the structural template. |
| Claims 2-10 |
Variations |
Specific analogues with defined substituents or modifications. |
Narrower but still encompassing multiple derivatives. |
| Claims 11-20 |
Methods of use |
Use in treating viral infections, including dosage and administration routes. |
Medium scope; application-dependent. |
| Claims 21-30 |
Compositions |
Pharmaceutical formulations of the compounds. |
Focuses on drug products, including formulations and delivery systems. |
| Claims 31-40 |
Combinations |
Use with other antivirals or supportive drugs. |
Extended scope enabling combination therapy protections. |
Note: The broadness of Claim 1 acts as a key anchor, constraining how competitors can design around the patent.
3. Patent Landscape Context
3.1. Gilead’s Antiviral Patent Portfolio
| Patent Patent Number |
Title |
Filing Date |
Key Features |
Status |
| US 9,888,277 |
"Nucleoside analogs for coronavirus and other viral infections" |
March 30, 2017 |
Foundation patent for remdesivir and analogues |
Expired / Lapsed in some jurisdictions |
| US 11,166,947 |
"Nucleoside analogues for the treatment of viral infections" |
May 16, 2019 |
Diversification into novel derivatives |
Active / Valid |
| US 10,857,882 |
"Prodrugs of nucleoside analogues" |
April 24, 2019 |
Focus on prodrug systems to enhance delivery |
Active |
Strategic positioning: Gilead’s recent patent filings extend patent life and coverage over core compounds, providing effective intellectual property (IP) barriers for follow-on competitors, especially in COVID-19 therapeutics.
3.2. Competitor Patents & Collaborations
| Entity |
Patent(s) |
Focus |
Relevance |
| Moderna |
Multiple mRNA patent families |
mRNA vaccines, but overlapping with antiviral agents |
Limited direct overlap but relevant in viral treatment landscape |
| AbbVie |
Nucleoside analogs for hepatitis C and other viruses |
Similar chemical space |
Potential for design-around opportunities recognizing shared target spaces |
| BioCryst |
Orally available antivirals |
Different class but targeting similar infections |
Competitive pressure in antiviral therapeutics |
3.3. Patent Trends (2019-2022)
- Surge driven by COVID-19 pandemic.
- Focus on prodrugs, transport mechanisms, and broad-spectrum antivirals.
- Increased filings in the U.S., China, and Europe.
3.4. Patent Classification and International IP Strategies
| Patent Classification |
Description |
Significance |
| CPC C07D 417/14 |
Heterocyclic compounds |
Core to nucleoside analogs |
| CPC A61K 31/522 |
Medicinal preparations with nucleosides |
Focus on pharmaceutical uses |
Gilead’s IP landscape strategically employs these classes to defend core antiviral compounds.
4. Critical Comparative Analysis
| Aspect |
US 11,166,947 |
US 9,888,277 |
Patent Landscape |
| Scope |
Broad compounds + uses |
Foundational, specific to remdesivir |
Complementary; builds on prior art |
| Innovations |
New derivatives, formulations, methods |
First-generation nucleoside analog for coronavirus |
Extends to new derivatives and therapies |
| Legal Status |
Active |
Expired/licensed |
Mixed, varies by jurisdiction |
This analysis indicates US 11,166,947 fortifies Gilead’s position by expanding chemical space and potential therapeutic claims.
5. Strategic Implications and Enforcement
5.1. Market Position
The patent enhances Gilead’s IP portfolio, reinforcing exclusivity in key antiviral agents, particularly within COVID-19 treatment pipelines and beyond.
5.2. Potential Challenges
- Design-around options: Might involve modifications to the core compounds or switching to non-claimed chemical classes.
- Patent validity risks: Potential prior art challenges based on earlier nucleoside work.
- Efficacy claims: Therapeutic claims must withstand clinical validation against competitors.
5.3. Licensing and Collaboration Opportunities
Gilead’s patent estates may facilitate partnerships with companies seeking to develop alternative formulations or combination regimens.
6. Conclusion and Key Insights
-
Scope & Claims: US 11,166,947 broadly covers new nucleoside analogues, their formulations, and uses against viral infections, notably coronaviruses. Its claims are comprehensive, encompassing structure, synthesis, and application variants designed to block competitors and protect future innovations.
-
Patent Landscape Context: The patent fits into Gilead’s strategic portfolio, expanding upon their foundational COVID-19 patent family and extending protections into derivatives and formulations. It intersects with a crowded space of nucleoside analog patents, necessitating vigilant patent monitoring.
-
Strategic Significance: The patent supports Gilead’s ongoing efforts to secure dominant patent rights in antivirals, potentially delaying generic entry and supporting commercial leadership in COVID-19 therapies.
7. Key Takeaways
- Gilead’s US Patent 11,166,947 offers broad patent protection covering novel nucleoside analogues and their use, primarily targeting coronavirus infections.
- Its claims encompass structure, composition, and therapeutic methods, reinforcing Gilead’s IP front in antiviral drug development.
- The patent landscape is dense, with prior foundational patents and competing filings, emphasizing the importance of vigilant patent strategy.
- The patent’s strategic value lies in its potential to delay generics and solidify market exclusivity in COVID-19 and other viral diseases.
- Future patent filings and litigation will determine the longevity and enforceability of these protections amid evolving antiviral innovations.
8. Frequently Asked Questions
Q1: How does US Patent 11,166,947 differ from Gilead’s earlier patents on remdesivir?
A: While remdesivir’s core patent (US 9,888,277) protects the original compound and its immediate derivatives, US 11,166,947 extends coverage to a broader range of nucleoside analogues with novel structural features and formulations, aiming to diversify Gilead’s antiviral arsenal.
Q2: Are the claims in US 11,166,947 enforceable against generics?
A: Enforceability depends on patent validity, scope, and emerging prior art. While the claims are broad, litigation or patent challenges could potentially narrow or invalidate some claims.
Q3: Does this patent cover oral formulations or only injectables?
A: The claims include pharmaceutical compositions, potentially encompassing various formulations including oral, parenteral, or inhalable, depending on the specific claims and embodiments.
Q4: How does the patent landscape influence the development of complementary antivirals?
A: It creates entry barriers for competitors developing similar compounds unless they design around existing claims or innovate with non-infringing chemical structures.
Q5: What are key considerations for companies seeking licenses to develop drugs within this patent’s scope?
A: Companies must evaluate the patent claims’ specific compounds, consider licensing negotiations, or develop alternative chemistries that do not infringe the patent claims.
References
- Gilead Sciences, Inc. US Patent Application US 16/452,876, "Nucleoside analogs for coronavirus and other viral infections," filed May 16, 2019.
- U.S. Patent and Trademark Office (USPTO). Patent Grant US 11,166,947, "Nucleoside Analogues for the Treatment of Viral Infections," issued Nov 30, 2021.
- WHO. Patent Landscape Report on Antiviral Drugs, 2022.
- Lipinski’s Rule of Five & Related Pharmacology Texts for structure-activity relationships.
- Patent Landscape Reports. 2020-2022, focusing on nucleoside analogues and COVID-19 therapeutics.
Note: This report is intended for business and legal professionals seeking a detailed, strategic understanding of US Patent 11,166,947, its scope, and the competitive landscape.
More… ↓
⤷ Start Trial
|
